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Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently
accompanied by TP53 mutation and identifies a tumour suppressor gene
locus at 5q13.1-21
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Summary Forty-nine ovarian tumours were examined for loss of heterozygosity (LOH) on chromosome 5
using eight microsatellite markers spanning both arms, including one at the APC locus. LOH on Sq was a
frequent event, detectable in 23 of 49 (47%) tumours, whereas 5p LOH was detected in only 1 of 22 tumours
(5%). Six tumours showed partial LOH on 5q, enabling the candidate region to be localised to a 22 cM region
proximal to APC, flanked by D5S424 and D5S644. An association was found between 5q LOH and TP53
mutation, with 18 of 23 (78%) tumours with LOH on Sq also harbouring a TP53 mutation. LOH on Sq was
observed in 6 of 18 (33%) stage I tumours, suggesting that it may be an early event in the molecular
pathogenesis of certain ovarian carcinomas.
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Tumorigenesis results from the accumulation of multiple
alterations in proto-oncogenes and tumour-suppressor genes
(TSGs). Loss ofheterozygosity (LOH) at specific chromosomal
segments is often associated with the loss of function of TSGs
and is frequently observed in a variety ofhuman malignancies
(reviewed by Weinberg, 1992). In ovarian cancer, multiple
chromosomal deletions on chromosomes 3, 6, 11, 17, 18 and 22
among others have been reported (Okamoto etal., 1991; Sato et
al., 1991; Yang-Feng et al., 1993; Cliby et al., 1993; Foulkes et
al., 1993a,b; Tavassoli et al., 1993; Englefield et al., 1994).
However, apartfrom TP53andBRCAI, theTSGswhich arethe
target ofthese allelic losses have not been cloned and in many
cases eventheirapproximate locationshave yetto bedefined. In
some cases, LOH analysis has identified regions containing
TSGs with proven involvement in other tumour types
prompting investigations of the role of the TSG in ovarian
cancer (Englefield et al., 1994; Foulkes et al., 1994). In
particular, allelic deletions on chromosome 5 have been
observed in ovarian carcinoma with the common region
consistent with inactivation of the APC gene. (Cliby et al.,
1993; Allan et al., 1994). However, in an extensive mutation
analysis, Allan etal. (1994) found noevidence ofAPCmutation,
arguing against its involvement in ovarian tumorigenesis. They
were able to confirm that chromosome 5 LOH was common in
ovarian cancer but were unable to refine the location of the
putativeTSG beyond anexclusion ofdistal 5p. In an attempt to
refine the location ofthe candidate region we have analysed for
LOH using seven polymorphic microsatellite markers on
chromosome Sq and one on Sp in a panel of 49 ovarian
tumours. The same panel of tumours was also analysed for
mutations in the TP53 gene.
Materials and methods
Tumour specimens and DNA extraction
Tumour and blood samples were obtained from 49 patients
undergoing surgery for primary ovarian cancer. The tumours
were collected from hospitals in and around Southampton
except for those suffixed 'm', which were obtained from
King's College Hospital, London, and the Royal Sussex
County Hospital, Brighton. Where possible tumours were
staged according to FIGO staging (Shepherd, 1989). DNA
was isolated from tumours and blood as described by
Foulkes et al. (1993a).
Polymerase chain reaction
Microsatellite markers for chromosome 5 were amplified by
the polymerase chain reaction (PCR) using the primers listed
in Table I. PCR reactions were performed in 15 p1 aliquots
containing 10 pmol of each primer, 200 giM each of dATP,
dTTP and dGTP, 50 mm dCTP, standard PCR reaction
buffer containing 1.5 mM magnesium chloride, 0.5 u Taq
DNA polymerase (Promega, USA), 50 ng of DNA and
0.05 mCi [o-32P]dCTP. PCR conditions consisted of 30 cycles
of 1 min at 94°C, 1 min at 53-58°C and 1 min at 72°C. The
PCR products were analysed on standard 6% (29:1
acrylamide-bis-acrylamide) denaturing and/or non-denatur-
ing polyacrylamide gels.
SSCP and sequencing analysis of TP53
PCR amplification of exons 5-8 of TP53 were performed
using the primers and conditions described by Milner et al.
(1993). SSCP analysis of the samples was performed as
described by Campbell et al. (1994). Tumour samples
showing abnormal band shifts were repeated together with
matching normal DNA to ensure that it was not due to a
germline polymorphism. DNA sequencing was performed on
some of the tumours with band shifts using a dideoxy
termination protocol (Foulkes et al., 1995).
Statistical analyses
Statistical analysis was performed using Spearman's rank
correlation (Gardner and Altman, 1989).
Results
LOH on chromosome 5
Forty-nine ovarian tumours were analysed for chromosome 5
LOH with up to eight microsatellite markers. One was
located at Spter (D5S417) and the other seven spanned the Sq
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Table I The sequence and location of chromosome 5 microsatellite markers
Locus/
marker Position Primers
D5S417 Spter TGGAAACTATGTATCTTGGAGG
AFM205 GCCGGCTTTAGGGTGG
D5S118 5cent-ql 1.2 CAATCTGTGACAGTTTCTCA
MFD63 CAAAACCAAAAAACCAAAGGC
D5S424 5ql3.1 -14 GGGTACATGGGAGTTCATTAGG
TCTCATGCTGGCAGGGATA
D5S644 5ql4-21 ACTAACTGGTAGATCAATGTGC
TTGGATTTGCTAAGACTGTG
D5S346 5q21 -22 ACTCACTCTAGTGATAAATCGGG
APC AGCAGATAAGACAAGTATTAC-
TAGTT
IL9 5q22.3-q31.3 CTAATGCAGAGATTTAGGGC
GTGGTGTAAAGACTGCATAG
D5S399 5q22.3-q31.3 GAGTGTATCATGCAGGGTGC
GGCCTCAACTTATAATCAA
D5S209 5q31.3-33.3 CTGCACTAGAAAGGCAGAGT
MFD1 16 TGCAGCACCAAACACCAAGT
aPrimer sequences are indicated in the 5' to 3' direction.
arm, including one at the APC gene locus (D5S346). The
LOH data together with the tumour histology and stage are
presented in Table II. LOH of any marker on 5q was
detected in 23 of 49 (47%) tumours. In contrast, LOH of the
Spter marker (D5S417) was detected in only 1 of 22 (5%)
informative tumours and no tumour was identified with LOH
on 5p only. In 13 tumours, partial LOH was detected. Seven
of these tumours (12m, 22, 27, 32, 36, 49 and 71) retained
heterozygosity at D5S417, three (1lm, 13m and 86) retained
heterozygosity at D5118 and a further two (47 and 95)
retained heterozygosity at D5S424 (Figure 1), thereby
excluding Sp and proximal Sq from the candidate region.
The Sq distal boundary of the candidate region is indicated
by tumours 71, 86 and 151, which show proximal Sq LOH
but retain heterozygosity for the distal markers D5S644
(tumour 151) and D5S346 (tumours 71 and 86), as shown in
Figure 1. The smallest common region of deletion defined by
these tumours is flanked by the markers D5S424 and D5S644
representing a genetic distance of approximately 22 cM
(Gyapay et al., 1994). This region at 5ql3.1-21 is proximal
to the APC locus.
Analysis of TP53 mutation
SSCP analysis of TP53 exons 5-8 detected abnormal band
shifts in 22 of the 49 (45%) tumours examined (Table II and
Table IV) in agreement with the frequency observed in a
number of other studies (Foulkes et al., 1995; Kohler et al.,
1993a,b). No band shifts were detected in the matching
normal DNA from these samples, indicating that these were
somatic alterations and not germline polymorphisms. Twelve
of these tumours were sequenced, and in all cases a somatic
mutation was detected. There was a striking concordance of
TP53 mutation with chromosome 5q deletions (P<0.001;
Table III). Eighteen of the 23 (78%) tumours with 5q LOH
also harboured a mutation in TP53 compared with only 4 of
26 tumours heterozygous for 5q markers.
Correlation ofSq LOH and TP53 mutation with tumour stage
and histogical subtype
The LOH on chromosomes 5q and TP53 mutation was
compared with tumour stage (Table IV). Six of 18 (33%)
stage I tumours showed LOH at Sq, four of which also
harboured TP53 mutations suggestive of the involvement of
these loci in early stages of the development of some ovarian
cancers. There was an increase in the incidence of both 5q
and TP53 mutation with advancing stage, although this
increase was not statistically significant. With respect to the
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Figure 1 Chromosome 5q allelic deletion pattern for ovarian
tumours 47, 71, 86, 95 and 151 showing partial LOH of 5q. A full
description of the LOH in these tumours is detailed in Table II.
C], no LOH; M, LOH. For each informative locus, the
autoradiograph of the normal (N) and tumour (T) DNA PCR
is shown to the right. Alleles for marker D5S424 and D5S644
were resolved on 8% non-denaturing polyacrylamide gels and
D5S346 and MFD116 were resolved on 6% denaturing
polyacrylamide gels.
main histological subtypes, 5q LOH is perhaps of less
relevance in mucinous tumours since LOH was detected in
only 20% (1/5) of the mucinous adenocarcinomas compared
with 61% (16/26) of serous and undifferentiated adenocarci-
nomas and 55% (5/9) of endometrioid carcinomas. Among
the other histological subtypes and borderline and benign
tumours only one of the two mixed Miillelrian tumours
showed 5q LOH.
Discussion
Deletions on chromosome 5 which include the APC gene
have been observed in a variety of malignancies other than
just colorectal cancer and include oesophageal, gastric,
pancreatic and lung carcinomas (Boynton et al., 1992;
D'Aminco et al., 1992; Hori et al., 1992a,b; Hosoe et al.,
1994). In ovarian cancers, chromosome 5q LOH has been
reported by some groups to be an infrequent event (Ehlen
and Dubeau, 1990; Sato et al., 1991; Yang-Feng et al., 1993)
while others have shown frequent deletions (Cliby et al.,
1993; Allan et al., 1994). These discrepancies are most likely5q LOH in ovarian cancer
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due to differences in the number, location and type of interstitial deletions permitting the refinement of the
polymorphic markers used in each study as well as the small candidate TSG locus to the 22cM region. flanked by
size of the tumour collections. The most comprehensive of D5S424 and D5S644 at 5q 13.1-21. This region is proximal
these studies used five markers on each chromosomal arm
and detected LOH in 50% of the 27 tumours examined
(Allan et al., 1994). The LOH was consistent with the loss of
APC, but no mutations were detected by SSCP in any of the
exons containing published mutations suggesting that another Table m Comparison between LOH on chromosome 5q and TP53 gene was the target of the deletions. mutationa
In the present study we analysed for chromosome 5 LOH mutationa using eight microsatellite markers to verify the high frequency TP53 mutationa TP53 normal
of LOH reported by some and refine the location of the Sq LOH 18 5
putative 5q TSG. Consistent with the frequencies reported by 5q Het 4 22
Cliby et al. (1993) and Allan et al. (1994) we detected LOH aCorrelation 0.631; P-value <0.001; 90% confidence interval (CI)
on 5q in 23 of49 ovarian tumours. Thirteen ofthese tumours (0.462-0.756). The correlations and theirP-values were calculated by
exhibited LOH on only part of 5q including two with Spearman's rank correlation.
Table II Tumour clinical, chromosome 5 LOH and TP53 mutation data
Tumour TP53 Codon, nucleotide and amino
number Typea Stage S417 S118 S424 S644 S346 IL9 S399 S209 mutationb acid changec
1lm AC/UD Ia Hetd Het LOH NI LOH exon 7 NS
12m SPAC Ia Het NI LOH NI NI exon 5 NS
13m SPAC Ia NI Het LOH NI NI exon 5 NS
17m AC/UD III NI LOH LOH LOH LOH exon 5 NS
21m SPAC na NI NI LOH NI NI exon7 NS
22 SPAC III Het LOH LOH LOH LOH NI NI NI exon 6 220, TAG>TGT, Tyr>Cys
26 SPAC III NI LOH LOH LOH LOH LOH NI LOH exon 7 242, TGC>TGG, Cys>Trp
27 AC/UD I Het LOH NI LOH LOH LOH NI NI n
30 EC III NI NI LOH NI NI LOH NI NI exon 8 273, CGT>TGT, Arg>Cys
32 SPAC III Het NI LOH LOH LOH NI NI NI n
36 EC Ia Het NI LOH LOH LOH LOH LOH LOH n
43 AC/UD II NI LOH NI LOH LOH LOH LOH NI exon 5 157, GTC>GAC, Val>Asp
45 SPAC III NI NI LOH NI LOH LOH NI NI exon 6 196, GGA>TGA, Arg>Stop
47 AC/UD II Het LOH NI exon 5 179, CGC>CAC, Arg>His
49 MMT III Het LOH LOH LOH LOH NI LOH LOH exon 8 276, GCC>GC, frame shift
63 AC/UD na LOH NI LOH NI LOH LOH LOH LOH exon 7 242, TGC>GGC, Cys>Gly
71 SPAC IIa Het NI LOH LOH Het NI NI Het exon 7 NS
86 SPAC Illa Het Het LOH LOH Het NI Het Het exon 5 151, CCC>CGC, Pro>Arg
95 EC II Het LOH NI n
121 MAC III NI LOH NI exon 5 NS
131 SAC III LOH LOH LOH exon 8 NS
146 EC Ic LOH NI LOH n
151 EC IIc LOH Het NI exon 7 NS
2m BSA Ic Het NI Het Het NI NI Het n
4m SA na Het NI NI Het NI n
lom EC Ia NI NI Het Het Het n
14 SPAC IIIb Het Het NI NI Het Het Het Het n
15m SPAC IIb Het NI Het NI Het n
16m CCC III Het NI Het NI Het n
18m SPAC III Het Het Het n
19 SPAC III Het NI Het Het Het NI NI NI n
20 BSA IIIa Het Het Het Het Het Het Het Het n
23 SPAC I Het NI Het NI Het NI Het Het n
40 MAC II Het NI Het NI Het NI Het Het n
48 SPAC III NI Het Het n
50 MAC I Het NI Het Het NI NI Het Het n
60 GCT Ia Het Het NI n
70 EC Ia Het Het Het Het Het NI Het n
75 MA na NI Het n
80 MAC Ia NI Het Het n
97 MMT III Het Het Het exon 7 NS
114 EC Ia Het NI NI n
119 SPAC Ic Het Het Het n
122 AC/UD III Het NI NI exon 5 174, AGG>AAG, Arg>Lys
124 GCT III NI Het Het n
128 EC Ic Het Het NI n
134 SPAC III Het Het Het exon 5 166, ins A, frame shift
135 SPAC Ic Het Het Het exon 5 156, 12bp deletion
144 MAC Ic Het Het NI n
'AC/UD, adenocarcinoma, undifferentiated lineage; SPAC, serous papillary (cyst) adenocarcinoma (including serous carcinoma, papillary
carcinoma and serousadenocarcinoma); MAC, mucinousadenocarcinoma; EC, endometrioidcarcinoma; CCC, clear cellcarcinoma; MMT, mixed
Mullerian tumour; GCT, granulosa cell tumour; SPA, serous papillary adenoma; BSA, borderline serous adenoma. bTP53 mutation in the exon
indicated as determined by SSCP analysis. cCodon, nucleotide change and amino acid alteration is indicated. NS, not sequenced. dHet,
constitutional heterozygosity without loss; LOH, constitutionalheterozygosity with loss in the tumourDNA; NI, constitutionalhomozygosity and
therefore uninformative with respect to allelic loss. Bold entries indicate the maximum extent of allelic deletion in each tumour.5q LOH n aW cew 000 M~~~~~~~~~~~~~~~ Tavassoi et al
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Table IV Association between LOH on 5q and TP53 mutation
with tumour stage
Tumour TP53 mutations/5q
stage TP53 imtationa 5q LOHb LOHc
I 4/18 (22%) 6/18 (33%) 3/6 (50%)
H 4/7 (57%) 5/7 (71%) 4/5 (80%)
HI 12/20 (60%) 10/20 (50%) 9/10 (90%)
Unstaged 2/4 (50%) 2/4 (50%) 2/2 (100%)
Totals" 22/49 (45%) 23/49 (47%) 18/23 (78%)
'Numbers of tumours with TP53 mutation over the number of
tumours of the stage indicated; figures in brackets are percentages.
bNumber oftumours with LOH anywhere on chromosome 5qdivided
by the total number of tumours of that stage with percentages in
brackets. 'Number of tumours with TP53 mutation divided by the
number of tumours with 5q LOH with percentages in brackets.
dNumber oftumours ofall stages with the indicated property.
to APC, thereby excluding it as the candidate TSG,
consistent with the absence of APC mutations in ovarian
cancer reported by Allan et al. (1994).
LOH on Sq occurred in six (33%) stage I tumours,
suggesting that it may be an early event in the development
of crtain ovarian cancers. This finding is inconsistent with
the study by Allan et al. (1994), who concluded Sq LOH was
a late event in ovarian carcinogenesis. However, their
conclusion was based on the absence of LOH in only three
low-grade tumours, highlighting a difficulty encountered in
studies of this type in ovarian cancer in which low-grade and
early-stage tumours are relatively uncommon. Nevertheless,
such studies are vital if the sequence of molecular genetic
events in ovarian tumorigenesis is to be unravelled.
Comparison of the presence of LOH on chromosome 5
with mutation in TP53 revealed a significant association
between the two genetic events (P<0.001). A similar
observation has been reported in colorectal carcinomas
(Smith et al., 1995), but this is more likely to reflect an
association with APC inactivation than with another Sq
TSG. Although the association between Sq LOH and TP53
mutation in ovarian cancer is striking, caution must be
exercised in attributing this to a functional link between
TP53 and the putative Sq TSG as this might simply reflect
generalised chromosomal instability in tumours with advan-
cing stage. Only when the Sq TSG is cloned and it can be
examined for specific inactivating mutations will it be possible
to determine the true relationship between the two events.
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